Comparison of Ezetimibe/Simvastatin 10/20 mg Versus Atorvastatin 20 mg in Achieving a Target Low Density Lipoprotein-Cholesterol Goal for Patients With Very High Risk
- Author(s)
- Yun-Kyeong Cho; Seung-Ho Hur; Chun-Duk Han; Hyoung-Seob Park; Hyuck-Jun Yoon; Hyungseop Kim; Chang-Wook Nam; Yoon-Nyun Kim; Kwon-Bae Kim; Nam-Hee Park; Hee-Jun Park
- Keimyung Author(s)
- Cho, Yun Kyeong; Hur, Seung Ho; Park, Hyoung Seob; Yoon, Hyuck Jun; Kim, Hyung Seop; Nam, Chang Wook; Kim, Yoon Nyun; Kim, Kwon Bae; Park, Nam Hee; Park, Hee Jun
- Department
- Dept. of Thoracic & Cardiovascular Surgery (흉부외과학)
Dept. of Biomedical Engineering (의용공학과)
Dept. of Internal Medicine (내과학)
- Journal Title
- Korean Circulation Journal
- Issued Date
- 2011
- Volume
- 41
- Issue
- 3
- Keyword
- Ezetimibe; Simvastatin; Atorvastatin
- Abstract
- Background and Objectives: Although recent lipid-lowering therapies are effective in reducing low density lipoprotein-cholesterol (LDL-C) levels, many patients treated with lipid-lowering agents do not achieve target LDL-C levels, especially in very high risk patients. The aim of this study is to compare the effect of ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg on achieving a target LDL-C goal in very high risk patients. Subjects and Methods: A total of 74 patients with very high risk were enrolled in the study. Very high risk patients were defined as patients that displayed established cardiovascular disease with multiple major risk factors, poorly controlled risk factors, multiple risk factors of the metabolic syndrome and acute coronary syndromes. Patients were randomized into two groups: ezetimibe/simvastatin 10/20 mg (n=36) and atorvastatin 20 mg (n=38). Follow-up lipid profile was obtained 6 weeks later. A target goal of LDL-C was defined as less than 70 mg/dL at follow-up. Results: Baseline clinical and laboratory data were similar between the two groups. Achieving a target LDL-C goal was observed in 41.7% of Group 1 and 44.7% of Group 2 at 6 weeks (p=0.82). Changes in other lipid profiles were not significantly different but the tolerability of the two groups was similar. Conclusion: Ezetimibe/simvastatin 10/20 mg and atorvastatin 20 mg showed similar effects in achieving target LDL-C levels in patients with very high risk.
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.